LifeStance Health Group, Inc. (LFST) Form 10-Q — Nov 5, 2026
LifeStance Health delivered strong Q3 2026 results with revenue of $455.9 million, up 25% year-over-year, and net income of $22.4 million versus $1.1 million in the prior-year quarter. Nine-month revenue reached $1.29 billion (+24%) with net income of $60.2 million versus a $2.0 million loss a year ago. Growth was driven by a net increase of 867 clinicians (8,863 total), an 17% jump in patient visits to 2.7 million in the quarter, and modest payor rate increases. Adjusted EBITDA rose 70% to $68.4 million, and operating cash flow nearly doubled to $170.0 million for the nine months.
Key figures
- Eps
- 0.06
- Revenue
- 455864000
- Net Income
- 22385000
- Revenue Yoy
- 25%
- Total Assets
- 2186283000
- Cash Position
- 218818000
- Shares Outstanding
- 380190724
- Visits 9m
- 7.8 million
- Visits q3
- 2.7 million
- Clinicians
- 8863
- Q3 2025 revenue
- 363809000
- Center margin q3
- 161402000
- Debt outstanding
- 271900000
- Nine month revenue
- 1294694000
- Q3 adjusted ebitda
- 68357000
- Repurchase remaining
- 75400000
- Nine month net income
- 60240000
- Repurchase dollars 9m
- 122430000
- Shares repurchased 9m
- 15000000
- Shares repurchased q3
- 2000000
- Operating cash flow 9m
- 170037000
- Q3 2025 adjusted ebitda
- 40209000
- Repurchase authorization
- 100000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.